文献速递心脏核医学肿瘤 PET/CT

使用111In-替尔曼诺cept靶向载脂蛋白E敲除小鼠动脉粥样硬化斑块中巨噬细胞的甘露糖受体表达

Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept.
PubMed 文献 · EJNMMI Res · 2017-05-03

本研究在载脂蛋白E敲除(ApoE-KO)小鼠模型中评估111In标记的替尔曼诺cept检测动脉粥样硬化斑块中甘露糖受体(MR)阳性巨噬细胞的潜力。结果显示111In-替尔曼诺cept在MR表达器官中蓄积,血液残留信号低,并在ApoE-KO小鼠斑块中检测到局灶信号,与苏丹IV阳性区域及MR阳性巨噬细胞浸润相关。

要点

  • 111In-替尔曼诺cept放射标记产率大于99%。
  • ApoE-KO小鼠斑块中检测到111In-替尔曼诺cept局灶信号,对照组主动脉未检测到信号。
  • 斑块摄取与苏丹IV阳性区域及MR阳性巨噬细胞内皮下聚集相关。

核心结论

  • 静脉注射后111In-替尔曼诺cept在MR表达器官中蓄积,血液残留信号低。
  • 111In-替尔曼诺cept在含MR表达巨噬细胞的小鼠动脉粥样硬化斑块中可检测到摄取,提示替尔曼诺cept是用于无创检测动脉粥样硬化斑块中巨噬细胞的有前景示踪剂。

研究设计与样本

  • 研究使用ApoE-KO小鼠模型评估111In标记的替尔曼诺cept靶向动脉粥样硬化斑块中MR阳性巨噬细胞的潜力。
  • 标记稳定性和生物分布先在对照小鼠(n=10)注射后1小时评估。
  • 体内成像研究中111In-替尔曼诺cept静脉注射至ApoE-KO(n=8)和对照(n=8)小鼠,注射后90分钟用专用动物SPECT/CT扫描。
  • 为测试斑块摄取特异性,一组ApoE-KO小鼠共注射过量未标记替尔曼诺cept。
  • 离体成像研究取ApoE-KO(n=9)和对照(n=4)小鼠全主动脉进行苏丹IV染色和放射自显影,冰冻切片用于免疫组化。

主要发现

  • 111In放射标记替尔曼诺cept产率大于99%。
  • 静脉注射后111In-替尔曼诺cept在MR表达器官(肝和脾)蓄积,注射后1小时血液残留信号低。
  • 共注射阻断剂量未标记替尔曼诺cept后,受体阳性器官中111In-替尔曼诺cept摄取降低1.5至3倍,证明MR结合特异性。
  • ApoE-KO小鼠动脉粥样硬化斑块中检测到局灶信号,而对照小鼠主动脉未检测到信号。
  • 放射自显影显示111In-替尔曼诺cept摄取与苏丹IV阳性区域相关,并与免疫组化证实的MR阳性巨噬细胞内皮下聚集相关。

关键数值与推荐

  • 111In放射标记替尔曼诺cept产率大于99%。
  • 共注射阻断剂量未标记替尔曼诺cept后,受体阳性器官中111In-替尔曼诺cept摄取降低1.5至3倍。
  • 体内成像扫描在注射后90分钟进行,生物分布评估在注射后1小时进行。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atherosclerotic plaque phenotypes are classified based on the extent of macrophage infiltration into the lesions, and the presence of certain macrophage subsets might be a sign for plaque vulnerability. The mannose receptor (MR) is over-expressed in activated macrophages. Tilmanocept is a tracer that targets MR and is approved in Europe and the USA for the detection of sentinel lymph nodes. In this study, our aim was to evaluate the potential of 111In-labelled tilmanocept for the detection of MR-positive macrophages in atherosclerotic plaques of apolipoprotein E-knockout (ApoE-KO) mouse model. METHODS: Tilmanocept was labelled with 111In. The labelling stability and biodistribution of the tracer was first evaluated in control mice (n = 10) 1 h post injection (p.i.). For in vivo imaging studies, 111In-tilmanocept was injected into ApoE-KO (n = 8) and control (n = 8) mice intravenously (i.v.). The mice were scanned 90 min p.i. using a dedicated animal SPECT/CT. For testing the specificity of 111In-tilmanocept uptake in plaques, a group of ApoE-KO mice was co-injected with excess amount of non-labelled tilmanocept. For ex vivo imaging studies, the whole aortas (n = 9 from ApoE-KO and n = 4 from control mice) were harvested free from adventitial tissue for Sudan IV staining and autoradiography. Cryosections were prepared for immunohistochemistry (IHC). RESULTS: 111In radiolabelling of tilmanocept provided a yield of greater than 99%. After i.v. injection, 111In-tilmanocept accumulated in vivo in MR-expressing organs (i.e. liver and spleen) and showed only low residual blood signal 1 h p.i. MR-binding specificity in receptor-positive organs was demonstrated by a 1.5- to 3-fold reduced uptake of 111In-tilmanocept after co-injection of a blocking dose of non-labelled tilmanocept. Focal signal was detected in atherosclerotic plaques of ApoE-KO mice, whereas no signal was detected in the aortas of control mice. 111In-tilmanocept uptake was detected in atherosclerotic plaques on autoradiography correlating well with Sudan IV-positive areas and associating with subendothelial accumulations of MR-positive macrophages as demonstrated by IHC. CONCLUSIONS: After i.v. injection, 111In-tilmanocept accumulated in MR-expressing organs and was associated with only low residual blood signal. In addition, 111In-tilmanocept uptake was detected in atherosclerotic plaques of mice containing MR-expressing macrophages suggesting that tilmanocept represents a promising tracer for the non-invasive detection of macrophages in atherosclerotic plaques.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Varasteh Z, Hyafil F, Anizan N, et al. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept. EJNMMI Res. 2017. PMID: 28470406. doi:10.1186/s13550-017-0287-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。